Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Francis Yao, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone415-514-0332
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. Hepatology. 2020 Feb 04. PMID: 32017165.
      View in: PubMed
    2. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. Surveillance for HCC after Liver Transplantation: Increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020 Jan 13. PMID: 31972705.
      View in: PubMed
    3. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. Hepatocellular carcinoma (HCC) patients listed in short wait regions remain advantaged for liver transplant (LT) following 2015 HCC policy change. Liver Transpl. 2019 Dec 13. PMID: 31833634.
      View in: PubMed
    4. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant. 2020 Feb; 20(2):333-347. PMID: 31710773.
      View in: PubMed
    5. Mehta N, Dodge JL, Yao FY. REPLY. Hepatology. 2019 Oct; 70(4):1491-1492. PMID: 31095762.
      View in: PubMed
    6. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 Aug 02; 2(8):e1910326. PMID: 31469395.
      View in: PubMed
    7. Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology. 2019 Jul 25. PMID: 31344273.
      View in: PubMed
    8. Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. J Hepatocell Carcinoma. 2019; 6:93-103. PMID: 31355158.
      View in: PubMed
    9. DesJardin JT, Manicardi M, Svetlichnaya Y, Kolaitis NA, Papolos AI, Selby VN, Zier LS, Klein L, Aras MA, Yao FY, Roberts JP, De Marco T. Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates. Clin Transplant. 2019 Jul; 33(7):e13585. PMID: 31074522.
      View in: PubMed
    10. Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 Oct; 70(4):1185-1196. PMID: 30779440.
      View in: PubMed
    11. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 Aug; 19(8):2210-2218. PMID: 30861298.
      View in: PubMed
    12. Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25. PMID: 31168361.
      View in: PubMed
    13. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 Mar; 69(3):1193-1205. PMID: 30548884.
      View in: PubMed
    14. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 02; 25(2):228-241. PMID: 30198150.
      View in: PubMed
    15. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 02; 25(2):207-216. PMID: 30246323.
      View in: PubMed
    16. Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217. PMID: 30543796.
      View in: PubMed
    17. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2019 06; 21(6):731-738. PMID: 30391218.
      View in: PubMed
    18. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 10; 24(10):1346-1356. PMID: 30067889.
      View in: PubMed
    19. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl. 2018 09; 24(9):1171-1177. PMID: 29781162.
      View in: PubMed
    20. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018 08; 68(2):449-461. PMID: 29476694.
      View in: PubMed
    21. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 05; 102(5):816-822. PMID: 29505494.
      View in: PubMed
    22. Kotwani P, Saxena V, Dodge JL, Roberts J, Yao F, Hameed B. History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist. Transplantation. 2018 05; 102(5):794-802. PMID: 29319619.
      View in: PubMed
    23. Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 03; 24(3):327-329. PMID: 29351366.
      View in: PubMed
    24. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018 05; 18(5):1206-1213. PMID: 29068145.
      View in: PubMed
    25. Mehta N, Yao FY. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl. 2017 12; 23(12):1596-1600. PMID: 29024442.
      View in: PubMed
    26. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018 06; 16(6):955-964. PMID: 29175528.
      View in: PubMed
    27. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant. 2017 Nov; 31(11). PMID: 28881064.
      View in: PubMed
    28. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 09; 101(9):2071-2078. PMID: 28353492.
      View in: PubMed
    29. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. PMID: 28340509.
      View in: PubMed
    30. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500. PMID: 27838698.
      View in: PubMed
    31. Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 12; 151(6):1062-1065. PMID: 27983951.
      View in: PubMed
    32. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 10; 64(4):1178-88. PMID: 27481548.
      View in: PubMed
    33. Mehta N, Yao FY. Reply. Liver Transpl. 2016 08; 22(8):1164-5. PMID: 27097078.
      View in: PubMed
    34. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9. PMID: 27236153.
      View in: PubMed
    35. Mehta N, Roberts JP, Yao FY. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4. PMID: 26951991.
      View in: PubMed
    36. Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Curr Opin Organ Transplant. 2016 Apr; 21(2):91-8. PMID: 26807513.
      View in: PubMed
    37. Mehta N, Yao FY. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology. 2016 May; 63(5):1415-7. PMID: 26679367.
      View in: PubMed
    38. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016 Feb; 22(2):178-87. PMID: 26479422.
      View in: PubMed
    39. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4. PMID: 26718172.
      View in: PubMed
    40. Yao FY, Fidelman N. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging? Hepatology. 2016 Mar; 63(3):1014-25. PMID: 26560491.
      View in: PubMed
    41. Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015 Jun; 29(6):506-12. PMID: 25777321.
      View in: PubMed
    42. Young K, Fidelman N, Yao FY, Hills NK, Kohi MP, Kolli KP, Taylor AG, Kerlan RK. Implications of discordant findings between hepatic angiography and cross-sectional imaging in transplant candidates with hepatocellular carcinoma. Liver Transpl. 2015 Apr; 21(4):454-67. PMID: 25678220.
      View in: PubMed
    43. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015 Mar 31; 15:206. PMID: 25884197.
      View in: PubMed
    44. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77. PMID: 25689978.
      View in: PubMed
    45. Vagefi PA, Dodge JL, Yao FY, Roberts JP. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015 Feb; 21(2):187-94. PMID: 25371243.
      View in: PubMed
    46. Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant. 2015 Jan; 29(1):52-9. PMID: 25366656.
      View in: PubMed
    47. Yao FY, Hameed B, Mehta N, Roberts JP. Response to letter to the editors. Liver Transpl. 2014 Oct; 20(10):1285. PMID: 25155484.
      View in: PubMed
    48. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8. PMID: 25045002.
      View in: PubMed
    49. Sharpton SR, Feng S, Hameed B, Yao F, Lai JC. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation. 2014 Sep 15; 98(5):557-62. PMID: 24717221.
      View in: PubMed
    50. Flemming JA, Vagefi PA, Freise CE, Yao FY, Terrault NA. Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience. Liver Transpl. 2014 Oct; 20(10):1202-10. PMID: 24961679.
      View in: PubMed
    51. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014 Aug; 20(8):945-51. PMID: 24797281.
      View in: PubMed
    52. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014 Aug; 20(8):937-44. PMID: 24797145.
      View in: PubMed
    53. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8. PMID: 24493311.
      View in: PubMed
    54. Yao FY. Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment? Liver Transpl. 2014 Mar; 20(3):257-60. PMID: 24493329.
      View in: PubMed
    55. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013 Dec; 19(12):1343-53. PMID: 24285611.
      View in: PubMed
    56. Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl. 2013 Dec; 19(12):1318-23. PMID: 24039140.
      View in: PubMed
    57. Mehta N, Yao FY. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013 Oct; 19(10):1055-8. PMID: 23959652.
      View in: PubMed
    58. Yao F, Mehta N. Reply: To PMID 23333661. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1674. PMID: 24035772.
      View in: PubMed
    59. Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013 May; 11(5):572-8. PMID: 23333661.
      View in: PubMed
    60. Garwood ER, Fidelman N, Hoch SE, Kerlan RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl. 2013 Feb; 19(2):164-73. PMID: 23008091.
      View in: PubMed
    61. Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant. 2012 Jul-Aug; 26(4):E359-64. PMID: 22693962.
      View in: PubMed
    62. Kwan SW, Fidelman N, Ma E, Kerlan RK, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012 Jun; 18(6):727-36. PMID: 22344899.
      View in: PubMed
    63. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):354-62. PMID: 22083023.
      View in: PubMed
    64. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011 Oct; 17 Suppl 2:S109-16. PMID: 21584927.
      View in: PubMed
    65. Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011 Aug; 17(8):934-42. PMID: 21438129.
      View in: PubMed
    66. Sapisochin G, Yao FY, Roberts JP. Do preoperative inflammatory markers impact on outcome after liver transplantation for hepatocellular carcinoma? Ann Surg. 2011 Aug; 254(2):383; author reply 383-4. PMID: 21694577.
      View in: PubMed
    67. Ladabaum U, Cheng SL, Yao FY, Roberts JP. Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2011 Mar-Apr; 25(2):283-91. PMID: 20156221.
      View in: PubMed
    68. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010 Aug; 16(8):925-9. PMID: 20658555.
      View in: PubMed
    69. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008 Sep; 48(3):819-27. PMID: 18688876.
      View in: PubMed
    70. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008 Oct; 8(10):1982-9. PMID: 18727702.
      View in: PubMed
    71. Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant. 2008 Jun; 13(3):234-40. PMID: 18685309.
      View in: PubMed
    72. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, Bhoori S, Lee SG. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008 Apr; 15(4):1001-7. PMID: 18236119.
      View in: PubMed
    73. Hirose R, Yao F, Stock P, Roberts J, Ascher N. Liver transplantation at UCSF--a 20-year experience. Clin Transpl. 2008; 119-25. PMID: 19708450.
      View in: PubMed
    74. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007 Nov; 7(11):2587-96. PMID: 17868066.
      View in: PubMed
    75. Yao FY. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Hepatol Res. 2007 Sep; 37 Suppl 2:S267-74. PMID: 17877493.
      View in: PubMed
    76. Yao FY. Liver transplantation for hepatocellular carcinoma: the hepatitis C quandary. Liver Transpl. 2007 Jun; 13(6):783-5. PMID: 17538996.
      View in: PubMed
    77. Chao SD, Roberts JP, Farr M, Yao FY. Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant. 2007 Jun; 7(6):1594-600. PMID: 17430396.
      View in: PubMed
    78. Yao FY. Should surveillance for hepatocellular carcinoma be increased in patients with cirrhosis and small liver nodules? Nat Clin Pract Gastroenterol Hepatol. 2006 Oct; 3(10):544-5. PMID: 17008923.
      View in: PubMed
    79. Yao FY, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant. 2006 Sep-Oct; 20(5):617-23. PMID: 16968488.
      View in: PubMed
    80. Yao FY. Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation--yes. Semin Liver Dis. 2006 Aug; 26(3):239-47. PMID: 16850373.
      View in: PubMed
    81. Yao FY. Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number? Liver Transpl. 2006 Aug; 12(8):1189-91. PMID: 16868948.
      View in: PubMed
    82. Yao FY, Hirose R, LaBerge JM, Davern TJ, Bass NM, Kerlan RK, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005 Dec; 11(12):1505-14. PMID: 16315294.
      View in: PubMed
    83. Cruz E, Ascher NL, Roberts JP, Bass NM, Yao FY. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome. Clin Transplant. 2005 Aug; 19(4):501-6. PMID: 16008595.
      View in: PubMed
    84. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005 Apr; 5(4 Pt 1):795-804. PMID: 15760404.
      View in: PubMed
    85. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2005 Jan; 3(1):75-84. PMID: 15645408.
      View in: PubMed
    86. Yao FY, Roberts JP. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time? Liver Transpl. 2004 Jul; 10(7):919-21. PMID: 15237378.
      View in: PubMed
    87. Yao FY, Bass NM, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl. 2004 May; 10(5):621-30. PMID: 15108253.
      View in: PubMed
    88. Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology. 2004 Jan; 39(1):230-8. PMID: 14752842.
      View in: PubMed
    89. Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant. 2003 Nov; 3(11):1413-7. PMID: 14525603.
      View in: PubMed
    90. Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl. 2003 Jul; 9(7):684-92. PMID: 12827553.
      View in: PubMed
    91. Yao FY. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J Clin Gastroenterol. 2003 May-Jun; 36(5):440-2. PMID: 12702990.
      View in: PubMed
    92. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002 Oct; 8(10):873-83. PMID: 12360427.
      View in: PubMed
    93. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002 Sep; 8(9):765-74. PMID: 12200775.
      View in: PubMed
    94. Yao F, Terrault N. Hepatitis C and hepatocellular carcinoma. Curr Treat Options Oncol. 2001 Dec; 2(6):473-83. PMID: 12057093.
      View in: PubMed
    95. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001 Aug; 34(2):411-6. PMID: 11481627.
      View in: PubMed
    96. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001 Jun; 33(6):1394-403. PMID: 11391528.
      View in: PubMed
    97. Bass NM, Yao FY. The role of the interventional radiologist. Transjugular procedures. Gastrointest Endosc Clin N Am. 2001 Jan; 11(1):131-61. PMID: 11175979.
      View in: PubMed
    98. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol. 2000 Aug; 33(2):301-7. PMID: 10952248.
      View in: PubMed
    99. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg. 1999 Nov; 5(6):491-6. PMID: 10545536.
      View in: PubMed
    100. Yao FY. Elevated alpha-fetoprotein levels in hepatocellular carcinoma. Am J Gastroenterol. 1999 Nov; 94(11):3387. PMID: 10566766.
      View in: PubMed
    101. Yao F, Gish RG. Treatment of chronic hepatitis B: new antiviral therapies. Curr Gastroenterol Rep. 1999 Feb-Mar; 1(1):20-6. PMID: 10980922.
      View in: PubMed